Improving CAR T cell immunotherapy-mediated remissions for pediatric leukemia.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30985293.
- Also identified by DOI 10.1172/JCI128743 and PMC identifier 6486350.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR) T cells are an effective therapy for relapsed or refractory pediatric B cell leukemia. Analysis of the starting material, the T cells collected from the patient prior to CAR manufacture, reveals possible biomarkers of cells destined to perform poorly in patients. Long-term follow-up shows that long periods of B cell aplasia, a marker of in vivo CAR activity, are associated with longer remission but also a higher chance of antigen-negative relapse. The role of transplantation as consolidative therapy is unclear in this nonrandomized data, but clearly warrants further study.
Medical subject headings
- Receptors, Antigen, T-Cell
- T-Lymphocytes